Hematopoietic Agents Flashcards
Used prophylactically in pregnant women to prevent neural tube defects in the fetus:
A - Riboflavin
B - Pyridoxine
C - Iron
D - Vitamin B12
E - Folic acid
E - Folic acid
Indicated for use in patients suffering from cyclic neutropenia to stimulate neutrophil production:
A - Epoetin alfa
B - Filgrastim
C - Darbepoetin alfa
D - Romiplostim
E - Oprelvekin
B - Filgrastim
Therapy with folinic acid is used to treat anemia associated with the
A - antituberculosis drugs isoniazid and pyrazinamide.
B - antiparkinson drug levodopa.
C - antibiotic chloramphenicol.
D - anticancer agent carboplatin.
E - anticancer agent methotrexate.
E - anticancer agent methotrexate
Deficiency in folic acid is characterized by
A - microcytic, hypochromic anemia.
B - sideroblastic anemia.
C - neutropenia.
D - red-cell aplasia.
E - megaloblastic anemia.
E - megaloblastic anemia.
Which of the following agents activates the thrombopoietin receptor on megakaryocytes?
A - Epoetin alfa
B - Filgrastim
C - Darbepoetin alfa
D - Romiplostim
E - Oprelvekin
D - Romiplostim
Cyclosporine was one of the first immunosuppressants to be used for organ transplant therapy. The mechanism of action of cyclosporine is to
A - intercalate DNA in proliferating T cells.
B - block purine metabolism in proliferating T cells.
C - block CD52 on the surface of activated T cells.
D - block the protein phosphatase activity of calcineurin.
E - block the protein kinase activity of mTOR.
D - block the protein phosphatase activity of calcineurin.
Tacrolimus is one of the most effective immunosuppressant drugs in routine use. The mechanism of action of tacrolimus is to
A - intercalate DNA in proliferating T cells.
B - block guanine nucleotide synthesis in proliferating T cells.
C - block CD52 on the surface of activated T cells.
D - block the protein phosphatase activity of calcineurin.
E - block the protein kinase activity of mTOR.
D - block the protein phosphatase activity of calcineurin
Sirolimus is used in combination with other drugs in patients receiving organ transplants. The mechanism of action of sirolimus is to
A - intercalate DNA in proliferating T cells.
B - block guanine nucleotide synthesis in proliferating T cells.
C - block CD52 on the surface of activated T cells.
D - block the protein phosphatase activity of calcineurin.
E - block the protein kinase activity of mTOR.
E - block the protein kinase activity of mTOR.
Mycophenolate mofetil (MMF) is typically used in combination with other agents for immunosuppression pharmacotherapy. The mechanism of action of mycophenolate is to
A - intercalate DNA in proliferating T cells.
B - block guanine nucleotide synthesis in proliferating T cells.
C - block CD52 on the surface of activated T cells.
D - block the protein phosphatase activity of calcineurin.
E - block the protein kinase activity of mTOR.
B - block guanine nucleotide synthesis in proliferating T cells.
Adalimumab is a monoclonal antibody used in a variety of autoimmune diseases. The molecular target of adalimumab is
A - CD3 on T lymphocytes.
B - IL-2 receptor on T cells.
C - CD52 on lymphocytes, monocytes, macrophages, and natural killer cells.
D - TNF-α.
E - IL-1.
D - TNF-α.
A 19-year-old woman with lethargy and fatigue is found
to have a blood hemoglobin level of 9.8 g/dL (normal
range 12–16 g/dL), a low erythrocyte corpuscular volume,
and a low erythrocyte hemoglobin concentration.
(A) cyanocobalamin
(B) epoetin
(C) ferrous fumarate
(D) filgrastim
(E) folic acid
(C) ferrous fumarate
A 47-year-old woman exhibits severe neutropenia after
a course of chemotherapy for breast cancer.
(A) cyanocobalamin
(B) epoetin
(C) ferrous fumarate
(D) filgrastim
(E) folic acid
(D) filgrastim
A 66-year-old man with progressive fatigability and
anorexia is found to have a low blood hemoglobin
concentration, an elevated mean corpuscular volume,
and an elevated serum concentration of methylmalonic
acid.
(A) cyanocobalamin
(B) epoetin
(C) ferrous fumarate
(D) filgrastim
(E) folic acid
(A) cyanocobalamin
A 68-year-old man with diabetic nephropathy and
end-stage renal disease exhibits peripheral
reticulocytopenia and anemia.
(A) cyanocobalamin
(B) epoetin
(C) ferrous fumarate
(D) filgrastim
(E) folic acid
(B) epoetin
Pegylation of a recombinant protein is employed for
which purpose?
(A) increasing oral bioavailability
(B) decreasing renal excretion rate
(C) increasing duration of action
(D) increasing binding to receptors
(E) reducing adverse effects
(C) increasing duration of action
